Re-evaluating design specifications of longitudinal clinical trials without unblinding when the key response is rate of change
- 30 October 1995
- journal article
- Published by Wiley in Statistics in Medicine
- Vol. 14 (20) , 2239-2248
- https://doi.org/10.1002/sim.4780142007
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Sample Size Reestimation for Triple Blind Clinical TrialsDrug Information Journal, 1993
- Design of the Lung Health Study: A randomized clinical trial of early intervention for chronic obstructive pulmonary diseaseControlled Clinical Trials, 1993
- The Effect of Finasteride in Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1992
- Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast CancerNew England Journal of Medicine, 1992
- Interim analyses for monitoring clinical trials that do not materially affect the type I error rateStatistics in Medicine, 1992
- Sample size re-estimation without unblinding for normally distributed outcomes with unknown varianceCommunications in Statistics - Theory and Methods, 1992
- The modification of diet in renal disease study groupControlled Clinical Trials, 1991
- A controlled dose‐ranging study of remoxipride and haloperidol in schizophrenia ‐ a Canadian multicentre trialActa Psychiatrica Scandinavica, 1990
- The power to detect differences in average rates of change in longitudinal studiesStatistics in Medicine, 1990
- The role of internal pilot studies in increasing the efficiency of clinical trialsStatistics in Medicine, 1990